Ivabradine for treating chronic heart failure
KEYWORDS: ivabradine, heart, failure, heart failure, population, committee, manufacturer, authorisation, marketing, marketing authorisation, patients, rate, standard, trial, mortality

from the clinical specialists that it was debatable whether the NYHA class 4 subgroup could be considered to be in a stable condition given the severity of their heart failure and that ivabradine is contraindicated in unstable heart failure. The committee also heard from the clinical specialists that the benefit observed in this subgroup of people would be expected because they are the population with the greatest risk of cardiovascular mortality. However, the committee noted that the analysis in this subgroup of people with NYHA class 4 heart failure was based on small numbers, which limits the robustness of the results. Therefore, the committee concluded that the effectiveness of ivabradine in people with NYHA class 4 heart failure was uncertain because of the small patient numbers in the analysis, which meant that these people could not be considered separately as a subgroup. 4.9 The committee discussed the position of ivabradine in the treatment pathway for chronic heart failure, noting that it is indicated in chronic heart failure NYHA class 2 to 4 with systolic dysfunction, for people in sinus rhythm whose heart rate is 75 bpm or more, and in combination with standard therapy including beta- blocker therapy or when
